Psych CASC / OSCE · Psychopharmacology — anxiolytics and hypnotics
Negotiating short-term hypnotic use and a deprescribing plan (CASC)
CASC-style station: explain GABA-A risks in older adults, refuse automatic Z-drug swap as a safety solution, offer CBT-I/sleep strategies and optional modest melatonin, and co-design a gradual taper with falls safety-netting.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes. Explain why long-term temazepam is no longer the safest plan after falls, address the Z-drug myth, and negotiate a gradual deprescribing plan with sleep supports. Include the daughter without talking over the patient. Avoid scaremongering and avoid false safety guarantees.[1][2][4]
Marking domains
Empathy and agenda; accurate plain-language mechanism (calming brain pathways that become less helpful and more hazardous over time); falls and cognition risk grounded in older-adult evidence; clear statement that Z-drugs still act on related GABA systems and are not a free pass; shared taper plan (pace, follow-up, what if rebound insomnia); CBT-I/sleep hygiene and optional modest melatonin; safety-net for severe withdrawal symptoms (rare but serious if abrupt stop).[1][5][6][7][8]
Model communication map
- Open: thank them; name the falls and sleep worry as twin goals — sleep without another broken hip.[1]
- Validate: long-term tablets often started for real grief insomnia; body adapts so stopping suddenly can feel awful — we will not abandon her.[5]
- Risk truth: in older adults, sedative-hypnotics give modest sleep gain with meaningful falls/cognition risk; guidelines list them as often inappropriate long-term.[1][2]
- Z-drug myth: switching to zolpidem is not a safety solution — related brain target, residual impairment and dependence potential still matter.[7][2]
- Plan: slow dose reductions (explain 10–25% style scaffolding in plain language), more time between steps if needed, written schedule, GP/psychiatry reviews.[4][5]
- Sleep supports: stimulus control, consistent rise time, CBT-I referral; optional melatonin with honest modest-expectation framing.[8][6]
- Education tool: patient-facing education can help people choose deprescribing (EMPOWER message) — offer leaflet/summary.[3]
- Safety-net: do not stop overnight; call if severe shaking, confusion, or seizure — reinstate cover then re-taper more slowly.[5]
- Close: questions; next appointment date; daughter as support not enforcer.
Common fails
- Agreeing to lifelong zolpidem as "safer benzodiazepine alternative."[7]
- Ordering abrupt cessation after four years continuous use.[5]
- Ignoring falls history while only discussing addiction stigma.[1]
- Over-promising perfect sleep on melatonin alone.[6]
- Speaking only to the daughter and sidelining the patient.
References
- [1]Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, 2005.PMID 16284208
- [2]By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc, 2023.PMID 37139824
- [3]Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial JAMA Intern Med, 2014.PMID 24733354
- [4]Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline Can Fam Physician, 2018.PMID 29760253
- [5]Soyka M Treatment of Benzodiazepine Dependence N Engl J Med, 2017.PMID 28328330
- [6]Ferracioli-Oda E, Qawasmi A, Bloch MH Meta-analysis: melatonin for the treatment of primary sleep disorders PLoS One, 2013.PMID 23691095
- [7]Gunja N The clinical and forensic toxicology of Z-drugs J Med Toxicol, 2013.PMID 23404347
- [8]Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update J Psychopharmacol, 2019.PMID 31271339